Back to search results

CX-2051 for Advanced Solid Tumors

This study is testing a new investigational drug called CX-2051, both alone and in combination with bevacizumab, for adults with advanced solid tumors. CX-2051 is an antibody-drug conjugate (ADC), which means it's designed to deliver a drug directly to cancer cells. The main goals are to understand the safety and side effects of CX-2051 and to find the best dose for future studies. You might be able to join if your cancer has progressed after standard treatments and you have a good performance status. The study aims to enroll 160 participants.

Study design
This is a first-in-human interventional study with an unspecified phase, enrolling about 160 participants. It has two parts: dose escalation to find the maximum tolerated dose, and dose expansion to further assess safety and preliminary anti-tumor activity.
What's involved
You would need to consent to a fresh biopsy or provide recent archival tumor tissue. Additional inclusion criteria may apply, and the study will assess safety and tolerability.
Compensation
Not stated in the trial record.
Follow-up
The safety and tolerability of CX-2051 will be measured for 44 months, and the recommended Phase 2 dose will be determined at 44 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06265688

First In Human Study of CX-2051 in Advanced Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
CytomX Therapeutics
~160 participants
Updated 2026-07-15 on ClinicalTrials.gov
What's tested:CX-2051Bevacizumab

At a glance

Recruiting sites
8 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and tolerability of CX-2051
Measured over 44 months
+1 more outcome measured

Conditions

Solid Tumor, Adult

Explore related trials

Solid Neoplasm

NCT06265688

Where you'd take part

This study runs at 8 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Carolina BioOncology Institute, PLLC

    Huntersville, North Carolinano site contact published

    Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusettsno site contact published

    Recruiting

  • Montefiore Medical Center

    The Bronx, New Yorkno site contact published

    Recruiting

  • NEXT Virginia

    Fairfax, Virginiano site contact published

    Recruiting

  • Sarah Cannon Research Institute at HealthONE

    Denver, Coloradono site contact published

    Recruiting

  • Sarah Cannon Research Institute, LLC

    Nashville, Tennesseeno site contact published

    Recruiting

  • START - Dallas/Fort Worth

    Fort Worth, Texasno site contact published

    Recruiting

  • START San Antonio LLC

    San Antonio, Texasno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Monika Vainorius, MD · STUDY_DIRECTOR · CytomX Therapeutics

Who to contact

Karen Deane
[email protected]
650-515-3185
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Measurable disease per RECIST v1.1
Consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue

Exclusion

Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated
Known active central nervous system (CNS) involvement by malignancy
Systemic anticancer treatment, radiotherapy, or investigational agent(s) within 14 days prior to C1D1
Previous treatment with antibody-drug conjugates (ADCs) with Topo-I inhibitor payload
Major surgery (requiring general anesthesia) within 4 weeks prior to C1D1
Elevated baseline laboratory values
Serious concurrent illness
Pregnant or breast feeding

What this trial measures

  • Safety and tolerability of CX-205144 months

    The number of participants experiencing a dose-limiting toxicity (DLT) as defined in the protocol, AEs (adverse events), and treatment-emergent adverse events (TEAEs) at any dose level

  • Determine the recommended Phase 2 dose (RP2D)44 months

    The number of participants experiencing a dose-limiting toxicity (DLT) as defined in the protocol, AEs (adverse events), and treatment-emergent adverse events (TEAEs) at any dose level